NephroGenex: Corporate Presentation (Nephrogenex) - Feb 9, 2015 - Anticipated patent expiry for method of use (including patient population and dosage) in EU in June 2029; Anticipated patent term extension in EU for method of use (including patient population and dosage) until 2034; Anticipated patent expiry for method of use (including patient population and dosage) in Canada in June 2024
Anticipated patent expiry • Renal Disease
|